19.03.19|Lilach BaumerThe clinical-stage company develops more efficient versions of existing successful drugs, including a long-acting version of Teva's multiple sclerosis cash cow
06.11.18|Lilach BaumerThe Xinchang, China-headquartered generic drugmaker is an existing investor, having made an initial $10 million investment in Mapi in 2016